{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:13Z","timestamp":1761541153770},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T00:00:00Z","timestamp":1373846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1752-1947-7-183","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T10:14:15Z","timestamp":1373883255000},"source":"Crossref","is-referenced-by-count":3,"title":["Angiotensin II type 1 receptor blocker-induced immune thrombocytopenia: a case report"],"prefix":"10.1186","volume":"7","author":[{"given":"Dhiren K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Bilkha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schnee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,15]]},"reference":[{"key":"2605_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1517\/14740338.1.2.173","volume":"1","author":"SD Zondor","year":"2002","unstructured":"Zondor SD, George JN, Medina PJ: Treatment of drug-induced thrombocytopenia. Expert Opin Drug Saf. 2002, 1: 173-180. 10.1517\/14740338.1.2.173.","journal-title":"Expert Opin Drug Saf"},{"key":"2605_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.7326\/0003-4819-137-8-200210150-00032","volume":"137","author":"S Ada","year":"2002","unstructured":"Ada S, Yalamanchili M, Friedenberg W: Immune thrombocytopenia after losartan therapy. Ann Intern Med. 2002, 137: 704-","journal-title":"Ann Intern Med"},{"key":"2605_CR3","unstructured":"Edarbi [package insert]. 2011, Deerfield, IL: Takeda Pharmaceuticals America, Inc"},{"key":"2605_CR4","unstructured":"Atacand [package insert]. 2012, Wilmington, DE: AstraZeneca, LP"},{"key":"2605_CR5","unstructured":"Teveten [package insert]. 2012, North Chicago, IL: Abbott Laboratories"},{"key":"2605_CR6","unstructured":"Avapro [package insert]. 2012, New York, NY: Bristol-Myers Squibb Sanofi-Synthelabo Partnership"},{"key":"2605_CR7","unstructured":"Cozaar [package insert]. 2011, Whitehouse Station, NJ: Merck & Co., Inc"},{"key":"2605_CR8","unstructured":"Benicar [package insert]. 2009, Parsippany, NJ: Daiichi Sankyo, Inc"},{"key":"2605_CR9","unstructured":"Micardis [package insert]. 2012, Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc"},{"key":"2605_CR10","unstructured":"Diovan [package insert]. 2012, East Hanover, NJ: Novartis Pharmaceuticals Corp"},{"key":"2605_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"2605_CR12","first-page":"1709","volume":"43","author":"DJ Michel","year":"1986","unstructured":"Michel DJ, Knodel LC: Comparison of three algorithms used to evaluate adverse drug reactions. Am J Hosp Pharm. 1986, 43: 1709-1714.","journal-title":"Am J Hosp Pharm"},{"key":"2605_CR13","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","volume":"129","author":"JN George","year":"1998","unstructured":"George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, Vondracek T: Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Int Med. 1998, 129: 886-890. 10.7326\/0003-4819-129-11_Part_1-199812010-00009.","journal-title":"Ann Int Med"},{"key":"2605_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001, 345: 851-869. 10.1056\/NEJMoa011303.","journal-title":"N Engl J Med"},{"key":"2605_CR15","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMoa042274","volume":"351","author":"AH Barnett","year":"2004","unstructured":"Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004, 351: 1952-1961. 10.1056\/NEJMoa042274.","journal-title":"N Engl J Med"},{"key":"2605_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMra066469","volume":"357","author":"RH Aster","year":"2007","unstructured":"Aster RH, Bougie DW: Drug-induced immune thrombocytopenia. N Engl J Med. 2007, 357: 580-587. 10.1056\/NEJMra066469.","journal-title":"N Engl J Med"},{"key":"2605_CR17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/asheducation-2009.1.153","volume":"1","author":"JN George","year":"2009","unstructured":"George JN, Aster RH: Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program. 2009, 1: 153-158.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2605_CR18","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","volume":"84","author":"TE Warkentin","year":"1994","unstructured":"Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, Kelton JG: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994, 84: 3691-3699.","journal-title":"Blood"},{"key":"2605_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"335","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet. 2000, 335: 637-645.","journal-title":"Lancet"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-7-183\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-7-183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-7-183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-7-183.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T19:07:46Z","timestamp":1596136066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-7-183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2605"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-7-183","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,15]]},"article-number":"183"}}